Table 3: Mammary gland lesion incidences by age and treatment group following prenatal exposure to bisphenol A (BPA), bisphenol AF (BPAF), and bisphenol S (BPS).

Lesion Development	Vehicle	BPA (mg/kg)			BPAF (mg/kg)			BPS (mg/kg)		
	0	0.5	5	50	0.05	0.5	5	0.05	0.5	5
3 months (n)	8	11	11	9	9	8	7	9	9	9
Inflammation, mixed cell	1	0	1	3	1	1	2	0	2	1
8 months (n)	5	8	5	5	7	5	6	3	5	5
Lobuloalveolar hyperplasia	0	0	1	0	0	0	0	0	0	0
Inflammation, mixed cell	0	0	0	0	0	0	1	0	0	0
Squamous metaplasia, ductal	0	0	0	0	0	0	1	0	0	0
14 months (n)	13	14	11	6	14	18	22	11	18	13
Carcinoma	0	0	0	0	0	0	0	0	2	0
Fibroadenoma	0	0	0	0	0	0	0	0	0	1
Histiocytic sarcoma	0	0	0	0	0	0	0	0	1	0
Lipoma	0	0	1	0	0	0	1	0	0	0
Cyst	0†	0	0	0	0	1	3	1	1	0
Duct dilation	0	0	0	1	0	0	0	0	0	0
Hemorrhage, focally extensive	0	0	0	1	0	0	0	0	0	0
Inflammation, Lymphoplasmacytic perivascular	2	5	3	3	7	7	5	2	11*	3
Inflammation, mixed cell	1††	0	0	0	1	2	8	2	6	2
Inflammation, neutrophilic	0	0	0	0	0	0	1	0	0	0
Inflammation, not specified	0	0	0	0	0	0	1	0	0	0
Keratin	0#	0	0	0	1	0	1	0	0	1
Lobuloalveolar hyperplasia	0††	3	2	1	0	1	5	0	5*	1
Lymph node: inflammation, neutrophilic	0	0	0	0	0	0	0	0	1	0
Lymph node: Inflammation, mixed with eosinophilic crystals	0	0	0	0	0	0	0	0	0	1
Lymph node: squamous cell carcinoma or met from zymbal's gland	0	0	0	0	0	0	1	0	1	0
Lymph node: vascular angiectasis	0	0	0	0	0	0	0	0	1	0
Lymph node: increased cellularity, plasma cells	0	0	0	0	0	0	1	0	0	0
Papillary hyperplasia, multifocal	0	0	0	0	0	0	0	0	1	0
Squamous metaplasia, ductal	0††	0	0	0	1	2	7*	1	4	1

Note: Six moribund animals necropsied between 11 and 12 mos. also displayed mixed cell inflammation (BPA: 5 & 50, BPAF: 0.05 & 0.5, and BPS 0.05 & 5 mg/kg) and are represented in Table S1

*Significantly differs from the control group by Fisher's exact test at $p < 0.05$.

Significant dose trends are shown in control columns:

† Significant trend for BPAF by the Cochran-Armitage trend test at $p < 0.05$; †† $p < 0.01$.

Significant trend for BPS by the Cochran-Armitage trend test at $p < 0.05$